Treatment options for skin and soft tissue infections: 'oldies but goldies'

International Journal of Antimicrobial Agents

Volumn 34, Issue SUPPL. 1, 2009, Pages

  Unal, Serhat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antibiotics; Antimicrobial resistance; Skin and soft tissue infections; Staphylococcus aureus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FLUCLOXACILLIN; FOLIC ACID ANTAGONIST; FUSIDIC ACID; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD DYSCRASIA; CLINICAL TRIAL; DRUG CHOICE; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; INFECTION; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STEVENS JOHNSON SYNDROME; STREPTOCOCCUS PYOGENES; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 67649227067     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(09)70545-X     Document Type: Article

References (34)

1. Jones M.E., Karlowsky J.A., Draghi D.C., Thornsberry C., Sahm D.F., and Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 22 (2003) 406-419
2. Jones M.E., Schmitz F.J., Fluit A.C., Acar J., Gupta R., and Verhoef J. Frequencyof occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme SENTRY Participants Group. Eur J Clin Microbiol Infect Dis 18 (1999) 403-408
3. Popovich K.J., and Hota B. Treatment and prevention of community-associated meticillin-resistant Staphylococcus aureus skin and soft tissue infections. Dermatol Ther 21 (2008) 167-179
4. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al., EMERGEncy ID Net Study Group. Meticillin resistant S. aureus infections among patients in the emergency department. N Engl J Med 355 (2006) 666-674
5. Bartlett J.G. Meticillin-resistant Staphylococcus aureus infections. Top HIV Med 16 (2008) 151-155
6. Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis 21 (2008) 122-128
7. Aksoy D.Y., and Unal S. New agents for treatment of Gram positive bacterial infections. Clin Microbiol Infect 14 (2008) 411-420
8. LeVecchio F., Perera N., Casanova L., Mulrow R.N., and Pohl A. Board-certified emergency physicians' treatment of skin and soft tissue infections in the community-acquired methicilin-resistant Staphylococcus aureus era. Am J Emerg Med 27 (2009) 68-70
9. Pallin D.J., Egan D.J., Pelletier A.J., Espinola J.A., Hooper D.C., and Camargo C.A. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of communityassociated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 51 (2008) 291-298
10. Szumowski J.D., Cohen D.E., Kanaya F., and Mayer K.H. Treatment and outcomes of infections by meticillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 51 (2007) 423-428
11. Kaka A.S., Rueda A.M., Shelburne S.A., Hulten K., Hamill R.J., and Musher D.M. Bactericidal activity of orally available agents against meticillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58 (2006) 680-683
12. Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jernigan J.A., et al., Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Meticillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
13. Markowitz N., Quinn E.L., and Saravolatz L.D. Trimethoprim-sulphamethoxazole compared to vancomycin for the treatment of Staphylococcus infection. Ann Intern Med 117 (1992) 390-398
14. Proctor R.A. Role of folate antagonists in the treatment of meticillinresistant Staphylococcus aureus infection. Clin Infect Dis 46 (2008) 584-593
15. Martinez-Aguilar G., Hammerman W.A., Mason Jr. E.O., and Kaplan S.L. Clindamycin treatment of invasive infections caused by community-acquired, meticillin-resistant and meticillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 22 (2003) 593-598
16. Hyun D.Y., Mason E.O., Forbes A., and Kaplan S.L. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community associated meticillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis 28 (2009) 57-59
17. Ruhe J.J., Monson T., Bradsher R.W., and Menon A. Use of long-acting tetracyclines for meticillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 40 (2005) 1429-1434
18. Ruhe J.J., and Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by meticillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 51 (2007) 3298-3303
19. Han L.L., McDougal L.K., Gorwitz R.J., Mayer K.H., Patel J.B., Sennott J.M., et al. High frequencies of clindamycin and tetracycline resistance in meticillinresistant Staphylococcus aureus pulsed-field type USA300 in a Boston ambulatory health center. J Clin Microbiol 45 (2007) 1350-1352
20. York M.K., Gibbs L., Perdreau-Remington F., and Brooks G.F. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol 37 (1999) 1727-1731
21. Nielsen H.U., Hammerum A.M., Ekelund K., Bang D., Pallesen L.V., and Frimodt-Moller N. Tetracycline and macrolide co-resistance in Streptococcus pyogenes: co-selection as a reason for increase in macrolide-resistant S. pyogenes?. Microb Drug Resist 10 (2004) 231-238
22. Clumeck N., Marcelis L., Amiri-Lamraski M.H., and Gordts B. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother 13 Suppl C (2003) 17-24
23. Cenizal M.J., Skiest D., Luber S., Bedimo R., David P., Fox P., et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of meticillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 51 (2007) 2628-2630
24. Enoch DA, Karas JA, Aliyu SH. Oral antimicrobial options for the treatment of skin and soft-tissue infections caused by meticillin-resistant Staphylococcus aureus in the UK. Int J Antimicrob Agents. Epub 2008 Dec 18.
25. Falagas M., Matthaiou D.K., and Vardakas K.Z. Fluoroquinolones vs. beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials. Mayo Clin Proc 81 (2006) 1553-1566
26. Goldstein E.J., Citron D.M., Warren Y.A., Tyrrell K.L., and Rybak M.J. Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against communityassociated and health care-associated meticillin-resistant and susceptible S. aureus. J Med Microbiol 57 (2008) 452-456
27. Niebuhr M., Mai U., Kapp A., and Werfel T. Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. Exp Dermatol 17 (2008) 953-957
28. Ong C.T., Kuti J.L., Nicolau D.P., and OPTAMA Program. Pharmacodynamic modeling of imipenem-cilastatin, meropenem and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Surg Infect (Larchmt) 6 (2005) 419-426
29. Cox V.C., and Zed P.J. Once-daily cefazolin and probenecid for skin and soft tissue infections. Ann Pharmacother 38 (2004) 458-463
30. Bradsher Jr. R.W., and Snow R.M. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med 77 (1984) 63-67
31. Levine D.P., Fromm B.S., and Reddy B.R. Slow response to vancomycin and vancomycin plus rifampin in meticillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115 (1991) 674-680
32. Stevens D.L. The role of vancomycin in the treatment paradigm. Clin Infect Dis 42 Suppl 1 (2006) S51-S57
33. Awad S.S., Elhabash S.I., Lee L., Farrow B., and Berger D.H. Increasing incidence of meticillin-resistant Staphylococcus aureus skin and soft tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg 194 (2007) 606-610
34. Sancar A.A., Yagenoglu S., DeVries R., Postma M.J., Simsek N., Pechlivanoglou P., et al. Vancomycin vs. teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital Pharm World Sci 30 (2008) 916-923